Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

NCT00003512 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No participants enrolled

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG: Antineoplaston therapy (Atengenal + Astugenal)

Sponsor

Burzynski Research Institute